» Articles » PMID: 36642915

Impaired Autophagy in Amyloid-beta Pathology: A Traditional Review of Recent Alzheimer's Research

Overview
Journal J Biomed Res
Specialty General Medicine
Date 2023 Jan 16
PMID 36642915
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. The major pathological changes in AD progression are the generation and accumulation of amyloid-beta (Aβ) peptides as well as the presence of abnormally hyperphosphorylated tau proteins in the brain. Autophagy is a conserved degradation pathway that eliminates abnormal protein aggregates and damaged organelles. Previous studies have suggested that autophagy plays a key role in the production and clearance of Aβ peptides to maintain a steady-state of Aβ peptides levels. However, a growing body of evidence suggests that autophagy is significantly impaired in the pathogenesis of AD, especially in Aβ metabolism. Therefore, this article reviews the latest studies concerning the mechanisms of autophagy, the metabolism of Aβ peptides, and the defective autophagy in the production and clearance of Aβ peptides. Here, we also summarize the established and new strategies for targeting autophagy and through clinical AD trials to identify gaps in our knowledge and to generate further questions.

Citing Articles

Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier.

Cazalla E, Cuadrado A, Garcia-Yague A Fluids Barriers CNS. 2024; 21(1):93.

PMID: 39574123 PMC: 11580557. DOI: 10.1186/s12987-024-00599-5.


The role of PI3K signaling pathway in Alzheimer's disease.

Pan J, Yao Q, Wang Y, Chang S, Li C, Wu Y Front Aging Neurosci. 2024; 16:1459025.

PMID: 39399315 PMC: 11466886. DOI: 10.3389/fnagi.2024.1459025.


Involvement of Autophagic Machinery in Neuropathogenesis: Targeting and Relevant Methods of Detection.

Sayed N, Ali A, Elsherbiny D, Azab S Methods Mol Biol. 2024; 2879:183-206.

PMID: 38441722 DOI: 10.1007/7651_2024_516.


The contribution of mitochondria-associated endoplasmic reticulum membranes (MAMs) dysfunction in Alzheimer's disease and the potential countermeasure.

Li Z, Cao Y, Pei H, Ma L, Yang Y, Li H Front Neurosci. 2023; 17:1158204.

PMID: 36960176 PMC: 10027904. DOI: 10.3389/fnins.2023.1158204.

References
1.
Lee S, Sato Y, Nixon R . Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci. 2011; 31(21):7817-30. PMC: 3351137. DOI: 10.1523/JNEUROSCI.6412-10.2011. View

2.
Faborode O, Dalle E, Mabandla M . Trauma-like exposure alters neuronal apoptosis, Bin1, Fkbp5 and NR2B expression in an amyloid-beta (1-42) rat model of Alzheimer's disease. Neurobiol Learn Mem. 2022; 190:107611. DOI: 10.1016/j.nlm.2022.107611. View

3.
Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Bachurin S . Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634):207-15. DOI: 10.1016/S0140-6736(08)61074-0. View

4.
Zhu C, Grossman H, Neugroschl J, Parker S, Burden A, Luo X . A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y). 2018; 4:609-616. PMC: 6240843. DOI: 10.1016/j.trci.2018.09.009. View

5.
Grimm M, Mett J, Stahlmann C, Haupenthal V, Zimmer V, Hartmann T . Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease. Front Aging Neurosci. 2014; 5:98. PMC: 3870290. DOI: 10.3389/fnagi.2013.00098. View